Discovery of Novel Fourth-Generation EGFR Inhibitors to Overcome C797S-Mediated Resistance

Zhu, YS; Ye, XQ; Shen, H; Li, JX; Cai, ZY; Min, WJ; Hou, Y; Dong, HJ; Wu, YX; Wang, LP; Wang, X; Xiao, YB; Yang, P

Wang, X; Xiao, YB; Yang, P (通讯作者),China Pharmaceut Univ, State Key Lab Nat Med, Nanjing 210009, Peoples R China.;Wang, X; Xiao, YB; Yang, P (通讯作者),China Pharmaceut Univ, Jiangsu Key Lab Drug Design & Optimizat, Nanjing 210009, Peoples R China.;Wang, X; Yang, P (通讯作者),China Pharmaceut Univ, Sch Pharm, Dept Med Chem, Nanjing 211198, Peoples R China.;Wang, X; Yang, P (通讯作者),China Pharmaceut Univ, Inst Innovat Drug Discovery & Dev, Nanjing 211198, Peoples R China.;Xiao, YB (通讯作者),China Pharmaceut Univ, Sch Pharm, Dept Pharmacol, Nanjing 211198, Peoples R China.;Xiao, YB (通讯作者),China Pharmaceut Univ, Chongqing Innovat Inst, Chongqing 401135, Peoples R China.

JOURNAL OF MEDICINAL CHEMISTRY, 2023; 66 (21): 14633

Abstract

Epidermal growth factor receptor (EGFR)-activating mutation is an important oncogenic driver of nonsmall cell lung cancer (NSCLC) patients. Osimertini......

Full Text Link